Jim Stengel will retire Oct. 31. Marc Pritchard, president of strategy productivity and growth, will take the reins.

Novasep is skilled in its ability to marry the competences of chemists and biochemists in developing syntheses and processes to produce molecules. By supporting the development and launch of new molecules, Novasep has a direct impact on everydaylife.By optimizing existing

acts as a UK distributor for a number of American and European pharmaceutical companies, providing access to a wide range of competitively priced, industry standard products, used in:Sterilizer validationProductionHygiene monitoringMicrobial quality controlEnvironmental monitoringOur comprehensive product range includes biological indicators for

Frito-Lay vp-marketing Gannon Jones talks about why really being green has created hot sales.

Known as 'Generation Buy,' these consumers buy what fits into their lifestyle.

Effort includes major online push, such as YouTube video contest and microsite.

Edwards Lifesciences has announced that its board of directors has authorized a new share repurchase program to acquire up to $250 million of the company's outstanding common shares.

Mannatech has announced that Judge Jeff Kaplan in the US District Court of Texas, Dallas Division, issued a memorandum opinion finding that Glycoproducts International infringed both Mannatech patents at issue in the case.

MabCure has completed the acquisition of a proprietary platform technology for the rapid and efficient generation of monoclonal antibodies.

Sanofi-Aventis has announced the opening of the offer by its wholly owned subsidiary Sanofi-Aventis Europe to acquire all issued ordinary shares, including shares held in the form of global depository shares, of Zentiva.

Repros Therapeutics has reported positive results from an interim analysis of its US Phase II endometriosis trial.

Amgen, which discovers, develops, manufactures and delivers innovative human therapeutics, has reached an agreement to settle its outstanding antitrust litigation with Ortho Biotech Products.

Neurogen has started a Phase II/III clinical trial in chronic insomnia patients with the company's insomnia agent, adipiplon. However, based upon reports from initial dosing of a higher than anticipated rate of unwanted next day effects, the company has suspended

Hoana Medical has partnered with a large healthcare system in Pennsylvania, the Veterans Administration with VA hospitals in Florida and Nebraska, and the US Army to improve patient safety in acute-care hospitals.

Micrus Endovascular has announced that the Vitesse intracranial stent study for ischemic therapy clinical trial application has received conditional approved from the FDA.

Nile Therapeutics has dosed the first acute setting heart failure patient in its Phase IIa, multi-center, open-label, ascending dose clinical study of the company's lead product candidate, CD-NP, a chimeric natriuretic peptide, in development for the treatment of acute decompensated

Schering-Plough and the European Organization for the Research and Treatment of Cancer have announced positive results from a randomized Phase III melanoma trial which showed that long-term treatment with pegylated interferon alfa-2b in stage III melanoma patients had a significant

NeurogesX has initiated dosing in its Phase I clinical trial of NGX-1998. The product candidate is a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.

Switzerland-based Roche has decided to discontinue its research on HIV drugs. It has terminated its HIV program that included compounds which were targeting two different ways to attack HIV.

Merck Sharp & Dohme has announced that Tredaptive 1g/20mg modified-release tablets, a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia, has received marketing approval in the EU, Iceland and Norway.